[suzierose]

TRAIL Trial recruiting patients @ NIH

by suzierose on Thu May 31, 2012 7:30 pm

Alternative immunotherapies are moving quickly from lab, mice to human. These therapies do not require high dose chemotherapy...stem cells are still harvested..but infused with genetically-modified materials (Rosenberg) or TRAIL to help body identify and kill cancer cells.

NCT00720785

"drug-induced sensitization to TRAIL could be used as a novel strategy to potentiate anticancer effects of autologous adoptively infused NK cells in patients with cancer. Murine studies conducted in our laboratory have also established that bortezomib treatment sensitizes tumors in vivo to killing by adoptively infused syngeneic NK cells; murine renal cell carcinoma line (RENCA) tumors in BALB/c mice grew significantly slower and survival was prolonged when syngeneic NK cell infusions were given following bortezomib treatment compared to mice receiving NK cell infusions alone or bortezomib alone. This anti-tumor effect was further potentiated by eradicating T-regulatory cells prior to adoptive NK cell infusion and by administering interleukin-2 after adoptive NK cell infusion. Recently, our laboratory has developed techniques for the in vitro isolation and expansion of NK cells to levels suitable for the treatment of cancer patients. Furthermore, we have also established good viability and sterility of these expanded NK cells which, compared to fresh NK cells, have increased surface expression of TRAIL and have enhanced cytotoxicity against tumor cells. We therefore propose this non-randomized, Phase I, dose escalating study designed to evaluate the safety and the anti- tumor effects of escalating doses of adoptively infused ex vivo expanded autologous natural killer (NK) cells against metastatic cancers or hematological malignancies sensitized to NK -TRAIL cytotoxicity with Bortezomib. "

Eligible pts:
Diagnosed with a hematological malignancy (multiple myeloma, chronic myelogenous leukemia [CML] or chronic lymphocytic leukemia [CLL] or small lymphocytic lymphoma [SLL]) and disease resistant or refractory to standard therapy

http://www.clinicalconnection.com/exp/EPVS.aspx?studyID=258994&slID=5179827